Abeona Therapeutics Inc vs Airbnb, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Airbnb, Inc. trades at $184.79 (market cap $110.76B). The key difference: Airbnb, Inc. is far larger — about 263× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | ABNB | |
|---|---|---|
Market Cap | $421.19M | $110.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $184.98 |
52-Week Low | $4.17 | $111.54 |
Enterprise Value | $276.10M | $101.19B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →